Amgen Unusual Options Activity
Whales with a lot of money to spend have taken a noticeably bearish stance on Amgen.Looking at options history for Amgen (NASDAQ:AMGN) we detected 10 trades.If we consider the specifics of each trade,
$1000 Invested In This Stock 15 Years Ago Would Be Worth $14,000 Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 6.43% on an annualized basis producing an average annual return of 19.36%. Currently, Vertex Pharmaceuticals
Top Performing Industry ETFs In June: Software Leads Returns, Chipmakers Attract Most Inflows
June closed on a high note for the stock market, with the S&P 500, tracked by the SPDR S&P 500 ETF Trust (NYSE:SPY), gaining 3.2%, despite significant disparities in sector and industry performances.T
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
These Three ETFs Look Ready for Breakout Moves, Roth MKM Says
RBC Capital Reiterates Sector Perform on Gilead Sciences, Maintains $74 Price Target
RBC Capital analyst Brian Abrahams reiterates Gilead Sciences (NASDAQ:GILD) with a Sector Perform and maintains $74 price target.
Gilead Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/01/2024 6.03% RBC Capital $74 → $74 Reiterates Sector Perform → Sector Perform 06/20/2024 14.63% Baird
Sector Update: Health Care Stocks Mixed Premarket Monday
Health care stocks were mixed premarket Monday as the Health Care Select Sector SPDR Fund (XLV) was 0.3% higher and the iShares Biotechnology ETF (IBB) was down 0.2% recently. SpringWorks Therapeutics
Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $150 Price Target
Cantor Fitzgerald analyst Olivia Brayer reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Neutral and maintains $150 price target.
Alnylam Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/01/2024 -38.4% Cantor Fitzgerald $150 → $150 Reiterates Neutral → Neutral 06/28/2024 18.27% UBS $253 →
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Ahead of Key US Jobs Reports
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1% and the actively traded Invesco QQQ Trust (QQQ) was 0.2% higher in Monday's premarket activity, ahead of key jobs reports
"Interest rate cuts + Trump's return" two major expectations continue to ferment! Will this benefiting sector see the dawn?
Market participants believe that in recent three years, the biotechnology sector has been underperforming the broader market. Once the expectation of interest rate cuts is raised by the Fed, biotechnology companies, represented by innovative drugs, will have the ability to make up ground.
Alnylam, Lilly, AstraZeneca Among Best Performing Pharmas, Biotechs in Q2
Moderna And Walgreens Boots Alliance Were Among The 10 Biggest Large Cap Losers Last Week (June 23 - June 29): Are These In Your Portfolio?
These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?Walgreens Boots Alliance, Inc. (NASDAQ:WBA) shares tumbled 24.12% after the company reported mixed Q3
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
Insulet Tops S&P 500 Growth Chart for Q2 as It Gains Market Share in the Diabetes Space
5 Analysts Assess IQVIA Hldgs: What You Need To Know
In the last three months, 5 analysts have published ratings on IQVIA Hldgs (NYSE:IQV), offering a diverse range of perspectives from bullish to bearish.The table below offers a condensed view of their
Why Are Carisma Therapeutics Shares Surging Friday?
Carisma Therapeutics Inc. (NASDAQ:CARM) shares are trading higher on Friday following the company's announcement of a significant development in its collaboration with Moderna.
What's Going On With Moderna Stock Friday?
Moderna, Inc. (NASDAQ:MRNA) stock is trending on Friday. The company announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for it
IQVIA Hldgs Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/28/2024 19.72% Barclays $275 → $255 Maintains Overweight 06/06/2024 26.77% Goldman Sachs → $270 Initiat